



5-27-05

JC10 Rec'd PCT/F 26 MAY 2005

PCT #3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	UCKUN ET AL.	Examiner:	UNKNOWN
Serial No.:	10/518,142	Group Art Unit:	UNKNOWN
Filed:	DECEMBER 17, 2004	Docket:	12152.125USWO
Title:	POKEWEED ANTIVIRAL PROTEIN POLYPEPTIDES WITH ANTIVIRAL ACTIVITY		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV495868934US

Date of Deposit: May 26, 2005

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

By: 

Name: David Ortiz

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

23552

PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449, 73 Reference(s), Copy of International Search Report
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

Merchant & Gould P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
612.332.5300

By: 

Name: Anne M. Murphy

Reg. No.: 54,327

AMurphy:PLSkaw



N 10/518,142

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	UCKUN ET AL.	Examiner:	UNKNOWN
Serial No.:	10/518,142	Group Art Unit:	UNKNOWN
Filed:	DECEMBER 17, 2004	Docket No.:	12152.125USWO
Title:	POKEWEED ANTIVIRAL PROTEIN POLYPEPTIDES WITH ANTIVIRAL ACTIVITY		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV495868934US

Date of Deposit: May 26, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By:

Name: David Ortiz

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

23552

PATENT TRADEMARK OFFICE

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. Enclosed for the Examiner's information is a copy of the International Search Report. At least some of the references were recently cited in an International Search Report mailed April 19, 2005.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. §1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date:

May 26, 2005

Anne M. Murphy
Anne M. Murphy
Reg. No. 54,327
AMM:PLSkaw

FORM P-4E INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.125USWO	Application Number: 10/518,142
	Applicant: UCKUN ET AL.	
	Filing Date: 12/17/2004	Group Art Unit: UNKNOWN

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,645,836	07/08/1997	Kitto			
	5,919,457	07/06/1999	Uckun			
	6,042,829	03/28/2000	Uckun et al.			
	6,146,628	11/14/2000	Uckun et al.			
	6,372,217 B1	04/16/2002	Uckun			
	6,689,362 B1	02/10/2004	Uckun			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Anderson, P. et al., "In Vitro and in Vivo Cytotoxicity of an Anti-Osteosarcoma Immunotoxin Containing Pokeweed Antiviral Protein," <i>Cancer Research</i> , Vol. 55, pp. 1321-1327 (March 15, 1995)
		Aron, G. et al., "Inhibition of Herpes Simplex Virus Multiplication by the Pokeweed Antiviral Protein," <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 17, No. 6, pp. 1032-1033 (June 1980)
		Barbieri, L. et al., "Purification and partial characterization of another form of the antiviral protein from the seeds of <i>Phytolacca americana</i> L. (pokeweed)," <i>Biochem. J.</i> , Vol. 203, pp. 55-59 (1982)
		D'Cruz, O. et al., "Pokeweed antiviral protein: a potential nonspermicidal prophylactic antiviral agent," <i>Fertility and Sterility</i> , Vol. 75, No. 1, pp. 106-114 (January 2001)
		D'Cruz, O. et al., "Effect of pretreatment of semen with pokeweed antiviral protein on pregnancy outcome in the rabbit model," <i>Fertility and Sterility</i> , Vol. 76, No. 4, pp. 830-833 (October 2001)
		D'Cruz, O. et al., "Mucosal Toxicity Studies of a Gel Formulation of Native Pokeweed Antiviral Protein," <i>Toxicologic Pathology</i> , Vol. 32, No. 2, pp. 212-221 (2004)
		D'Cruz, O. et al., "A 13-week subchronic intravaginal toxicity study of Pokeweed antiviral protein in mice," <i>Phytomedicine</i> , Vol. 11, pp. 342-351 (2004)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.125USWO	Application Number: 10/518,142
	Applicant: UCKUN ET AL.	
	Filing Date: 12/17/2004	Group Art Unit: UNKNOWN

	De Clercq, E., "Therapeutic potential of Cidofovir (HPMPC, Vistide™) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections," <i>Verhandelingen -- Koninklijke Academie Voor Geneeskunde Van Belgie</i> , Vol. 58, No. 1, pp. 19-47 (1996)
	Dore, J. et al., "Mutations dissociating the inhibitory activity of the pokeweed antiviral protein on eukaryote translation and <i>Escherichia coli</i> growth," <i>Nucleic Acids Research</i> , Vol. 21, No. 18, pp. 4200-4205 (1993)
	Ek, O. et al., "Antitumor Activity of TP3 (anti-p80)-Pokeweed Antiviral Protein Immunotoxin in Hamster Cheek Pouch and Severe Combined Immunodeficient Mouse Xenograft Models of Human Osteosarcoma," <i>Clinical Cancer Research</i> , Vol. 4, pp. 1641-1647 (July 1998)
	Ek, O. et al., "Combined Therapeutic Efficacy of the Thymidylate Synthase Inhibitor ZD1694 (TOMUDEX) and the Immunotoxin B43 (Anti-CD19)-PAP in a SCID Mouse Model of Human B-Lineage Acute Lymphoblastic Leukemia," <i>Leukemia and Lymphoma</i> , Vol. 28, pp. 509-514 (1998)
	Ek, O. et al., "Treatment of Human B-Cell Precursor Leukemia in SCID Mice by Using a Combination of the Anti-CD19 Immunotoxin B43-PAP with the Standard Chemotherapeutic Drugs Vincristine, Methylprednisolone, and L-Asparaginase," <i>Leukemia and Lymphoma</i> , Vol. 31, pp. 143-149 (1998)
	Erice, A. et al., "Anti-CD4 immunoconjugates containing pokeweed antiviral protein (PAP) inhibit both zidovudine (ZDV)-sensitive and ZDV-resistant clinical isolates of human immunodeficiency virus type I (HIV-1) in human T-lymphocytes," Received for publication by Blood Journal, pp. 1-23 (March 1992)
	Erice, A. et al., "Anti-Human Immunodeficiency Virus Type 1 Activity of an Anti-CD4 Immunoconjugate Containing Pokeweed Antiviral Protein," <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 37, No. 4, pp. 835-838 (April 1993)
	Gunther, R. et al., "In Vivo Anti-Leukemic Efficacy of Anti-CD7-Pokeweed Antiviral Protein Immunotoxin Against Human T-Lineage Acute Lymphoblastic Leukemia/Lymphoma in Mice with Severe Combined Immunodeficiency," <i>Leukemia</i> , Vol. 7, No. 2, pp. 298-309 (February 1993)
	Gunther, R. et al., "Biotherapy of Xenografted Human Central Nervous System Leukemia in Mice with Severe Combined Immunodeficiency Using B43 (Anti-CD19)-Pokeweed Antiviral Protein Immunotoxin," <i>Blood</i> , Vol. 86, No. 9, pp. 2537-2545 (May 1, 1995)
	Gunther, R. et al., "Toxicity Profile of the Investigational New Biotherapeutic Agent, B43 (Anti-CD19)-Pokeweed Antiviral Protein Immunotoxin," <i>Leukemia and Lymphoma</i> , Vol. 22, pp. 61-70 (1996)
	Hur, Y. et al., "Isolation and characterization of pokeweed antiviral protein mutations in <i>Saccharomyces cerevisiae</i> : Identification of residues important for toxicity," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 8448-8452 (August 1995)
	Irvin, J., "Pokeweed antiviral protein," <i>Pharmac. Ther.</i> , Vol. 21, pp. 371-387 (1983)
	Irvin, J. et al., "Pokeweed antiviral protein: ribosome inactivation and therapeutic applications," <i>Pharmac. Ther.</i> , Vol. 55, pp. 279-302 (1992)
	Jansen, B. et al., "Establishment of a Human t(4;11) Leukemia in Severe Combined Immunodeficient Mice and Successful Treatment Using Anti-CD19 (B43)-Pokeweed Antiviral Protein Immunotoxin," <i>Cancer Research</i> , Vol. 52, pp. 406-412 (January 15, 1992)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.125USWO	Application Number: 10/518,142
	Applicant: UCKUN ET AL.	
	Filing Date: 12/17/2004	Group Art Unit: UNKNOWN

	Jansen, B. et al., "Effective Immunochemotherapy of Human t(4;11) Leukemia in Mice with Severe Combined Immunodeficiency (SCID) Using B43 (Anti-CD19)-Pokeweed Antiviral Protein Immunotoxin Plus Cyclophosphamide," <i>Leukemia</i> , Vol. 7, No. 2, pp. 290-297 (February 1993)
	Kurinov, I. et al., "X-ray crystallographic analysis of the structural basis for the interactions of pokeweed antiviral protein with its active site inhibitor and ribosomal RNA substrate analogs," <i>Protein Science</i> , Vol. 8, pp. 1765-1772 (1999)
	Kurinov, I. et al., "X-Ray Crystallographic Analysis of Pokeweed Antiviral Protein-II after Reductive Methylation of Lysine Residues," <i>Biochemical and Biophysical Research Communications</i> , Vol. 275, No. 2, pp. 549-552 (2000)
	Kurinov, I. et al., "High resolution X-ray structure of potent anti-HIV pokeweed antiviral protein-III," <i>Biochemical Pharmacology</i> , Vol. 65, pp. 1709-1717 (2003)
	Kurinov, I. et al., "High Resolution X-Ray Structure and Potent Anti-HIV Activity of Recombinant Dianthin Antiviral Protein," <i>Arzneim.-Forsch./Drug Res.</i> , Vol. 54, No. 10, pp. 692-702 (2004)
	Lodge, J. et al., "Broad-spectrum virus resistance in transgenic plants expressing pokeweed antiviral protein," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 7089-7093 (August 1993)
	Messinger, Y. et al., "Treatment of Human B-Cell Precursor Leukemia in SCID Mice Using a Combination of the Investigational Biotherapeutic AGent B43-PAP with Cytosine Arabinoside," <i>Clinical Cancer Research</i> , Vol. 2, pp. 1533-1542 (September 1996)
	Messinger, Y. et al., "Evaluation of Temozolomide in a SCID Mouse Model of Human B-Cell Precursor Leukemia," <i>Leukemia and Lymphoma</i> , Vol. 33, Nos. 3-4, pp. 289-293 (1999)
	Miyashita, A. et al., "An approach to the synthesis of a papaverine analogue containing a quinazoline ring system," <i>Heterocycles</i> , Vol. 40, No. 2, pp. 653-660 (1995)
	Monzingo, A. et al., "The 2.5 Å Structure of Pokeweed Antiviral Protein," <i>J. Mol. Biol.</i> , Vol. 233, pp. 705-715 (1993)
	Mul, Y. et al., "Mechanism of inhibition of adenovirus DNA replication by the acyclic nucleoside triphosphate analogue (S)-HPMPApp: influence of the adenovirus DNA binding protein," <i>Nucleic Acids Research</i> , Vol. 17, No. 22, pp. 8917-8929 (1989)
	Myers, D. et al., "Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials," <i>Journal of Immunological Methods</i> , Vol. 136, pp. 221-237 (1991)
	Myers, D. et al., "Favorable Pharmacodynamic Features and Superior Anti-Leukemic Activity of B43 (Anti-CD19) Immunotoxins Containing Two Pokeweed Antiviral Protein Molecules Covalently Linked to each Monoclonal Antibody Molecule," <i>Leukemia and Lymphoma</i> , Vol. 18, pp. 93-102 (1995)
	Myers, D. et al. "An Anti-CD72 Immunotoxin Against Therapy-Refractory B-Lineage Acute Lymphoblastic Leukemia," <i>Leukemia and Lymphoma</i> , Vol. 18, pp. 119-122 (1995)
	Myers, D. et al., "Large Scale Manufacturing of TXU (Anti-CD7)-Pokeweed Antiviral Protein (PAP) Immunoconjugate for Clinical Trials," <i>Leukemia and Lymphoma</i> , Vol. 27, pp. 275-302 (1997)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.125USWO	Application Number: 10/518,142
	Applicant: UCKUN ET AL.	
	Filing Date: 12/17/2004	Group Art Unit: UNKNOWN

		Rajamohan, F. et al., "High-Level Expression and Purification of Biologically Active Recombinant Pokeweed Antiviral Protein," <i>Protein Expression and Purification</i> , Vol. 16, pp. 359-368 (1999)
		Rajamohan, F. et al., "Pokeweed Antiviral Protein Isoforms PAP-I, PAP-II, and PAP-III Depurinate RNA of Human Immunodeficiency Virus (HIV)-1," <i>Biochemical and Biophysical Research Communications</i> , Vol. 260, No. 2, pp. 453-458 (1999)
		Rajamohan, F. et al., "Deguanlylation of Human Immunodeficiency Virus (HIV-1) RNA by Recombinant Pokeweed Antiviral Protein," <i>Biochemical and Biophysical Research Communications</i> , Vol. 263, No. 2, pp. 419-424 (1999)
		Rajamohan, F. et al., "Modeling and Alanine Scanning Mutagenesis Studies of Recombinant Pokeweed Antiviral Protein," <i>The Journal of Biological Chemistry</i> , Vol. 275, No. 5, pp. 3382-3390 (February 4, 2000)
		Rajamohan, F. et al., "Expression of Biologically Active Recombinant Pokeweed Antiviral Protein in Methylotrophic Yeast <i>Pichia pastoris</i> ," Vol. 18, pp. 193-201 (2000)
		Rajamohan, F. et al., "Binding Interactions between the Active Center Cleft of Recombinant Pokeweed Antiviral Protein and the α -Sarcin/Ricin Stem Loop of Ribosomal RNA," <i>The Journal of Biological Chemistry</i> , Vol. 276, No. 26, pp. 24075-24081 (June 29, 2001)
		Rajamohan, F. et al., "Active Center Cleft Residues of Pokeweed Antiviral Protein Mediate its High-Affinity Binding to the Ribosomal Protein L3," <i>Biochemistry</i> , Vol. 40, No. 31, pp. 9104-9114 (2001)
		Ramakrishnan, S. et al., "Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation," <i>The Journal of Immunology</i> , Vol. 135, No. 5, pp. 3616-3622 (November 1985)
		Smith, C. et al., "In Vivo Treatment with Monoclonal Antibodies Directed Against CD4 and CD8 Antigens in Miniature Swine," <i>Journal of Immunotherapy</i> , Vol. 16, No. 2, pp. 105-114 (1994)
		Turner, N. et al., "C-terminal deletion mutant of pokeweed antiviral protein inhibits viral infection but does not depurinate host ribosomes," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 94, pp. 3866-3871 (April 1997)
		Uckun, F. et al., "Increased Efficiency in Selective Elimination of Leukemia Cells by a Combination of a Stable Derivative of Cyclophosphamide and a Human B-Cell-specific Immunotoxin Containing Pokeweed Antiviral Protein," <i>Cancer Research</i> , Vol. 45, pp. 69-75 (January 1985)
		Uckun, F. et al., "Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow," <i>The Journal of Immunology</i> , Vol. 134, No. 3, pp. 2010-2016 (March 1985)
		Uckun, F. et al., "Ex Vivo Elimination of Neoplastic T-Cells from Human Marrow Using an Anti-M, 41,000 Protein Immunotoxin: Potentiation by ASTA Z 7557," <i>Blut</i> , Vol. 50, pp. 19-23 (1985)
		Uckun, F. et al., "Ex vivo elimination of lymphoblastic leukemia cells from human marrow by mafosfamid," <i>Leukemia Research</i> , Vol. 9, No. 1, pp. 83-95 (1985)
		Uckun, F. et al., "Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia," <i>J. Exp. Med.</i> , Vol. 163, pp. 347-368 (February 1986)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.125USWO	Application Number: 10/518,142
	Applicant: UCKUN ET AL.	
	Filing Date: 12/17/2004	Group Art Unit: UNKNOWN

	Uckun, F. et al., "Pokeweed antiviral protein immunotoxins and their clinical potential for systemic prophylaxis/treatment of major complications of bone marrow transplantation in acute lymphoblastic leukemia," <i>Membrane-Mediated Cytotoxicity</i> , pp. 243-256 (1987)
	Uckun, F. et al., "Immunotoxins containing pokeweed antiviral protein against B-lineage restricted CD19 and HMW-BCGF receptors for cell-type specific anti-leukemic immunotherapy in human B-lineage acute lymphoblastic leukemias," <i>Human Tumor Antigens and Specific Tumor Therapy</i> , pp. 231-241 (1989)
	Uckun, F. et al., "In Vivo Efficacy of B43 (anti-CD19)-Pokeweed Antiviral Protein Immunotoxin Against Human Pre-B Cell Acute Lymphoblastic Leukemia in Mice with Severe Combined Immunodeficiency," <i>Blood</i> , Vol. 79, No. 9, pp. 2201-2214 (May 1, 1992)
	Uckun, F. et al., "In Vivo Efficacy of B43 (anti-CD19)-Pokeweed Antiviral Protein Immunotoxin Against BCL-1 Murine B-Cell Leukemia," <i>Blood</i> , Vol. 79, No. 10, pp. 2649-2661 (May 15, 1992)
	Uckun, F. et al., "Effective Immunochemotherapy of CALLA+Cμ+ Human Pre-B Acute Lymphoblastic Leukemia in Mice with Severe Combined Immunodeficiency Using B43 (anti-CD19) Pokeweed Antiviral Protein Immunotoxin Plus Cyclophosphamide," <i>Blood</i> , Vol. 79, No. 12, pp. 3116-3129 (June 15, 1992)
	Uckun, F. et al., "Developmental Hierarchy During Early Human B-Cell Ontogeny After Autologous Bone Marrow Transplantation Using Autografts Depleted of CD19+ B-Cell Precursors by an Anti-CD19 Pan-B-Cell Immunotoxin Containing Pokeweed Antiviral Protein," <i>Blood</i> , Vol. 79, No. 12, pp. 3369-3379 (June 15, 1992)
	Uckun, F. et al., "A phase II window of B43-PAP immunotoxin therapy in patients with therapy refractory B-lineage acute lymphoblastic leukemia undergoing bone marrow transplantation," University of Minnesota, 68 pages (August 1993)
	Uckun, F. et al., "Effects of the Intermolecular Toxin-Monoclonal Antibody Linkage on the <i>In Vivo</i> Stability, Immunogenicity and Anti-Leukemic Activity of B43 (Anti-CD19) Pokeweed Antiviral Protein Immunotoxin," <i>Leukemia and Lymphoma</i> , Vol. 9, pp. 459-476 (1993)
	Uckun, F. et al., "Allograft and Autograft Purging Using Immunotoxins in Clinical Bone Marrow Transplantation for Hematologic Malignancies," <i>Journal of Hematotherapy</i> , Vol. 2, pp. 155-163 (1993)
	Uckun, F. et al., "Pharmacokinetic Features, Immunogenicity, and Toxicity of B43(anti-CD19)-Pokeweed Antiviral Protein Immunotoxin in Cynomolgus Monkeys," <i>Clinical Cancer Research</i> , Vol. 3, pp. 325-337 (March 1997)
	Uckun, F. et al., "TXU (Anti-CD7)-Pokeweed Antiviral Protein as a Potent Inhibitor of Human Immunodeficiency Virus," <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 42, No. 2, pp. 383-388 (February 1998)
	Uckun, F. et al., "Toxicity, Biological Activity, and Pharmacokinetics of TXU (Anti-CD7)-Pokeweed Antiviral Protein in Chimpanzees and Adult Patients Infected with Human Immunodeficiency Virus," <i>The Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 291, No. 3, pp. 1301-1307 (December 1999)
	Uckun, F. et al., "Structure-Based Design and Engineering of a Nontoxic Recombinant Pokeweed Antiviral Protein with Potent Anti-Human Immunodeficiency Virus Activity," <i>Antimicrobial Agents and Chemotherapy</i> , Vol. 47, No. 3, pp. 1052-1061 (March 2003)
	Uckun, F. et al., "CNS activity of Pokeweed Anti-viral Protein (PAP) in mice infected with Lymphocytic Choriomeningitis Virus (LCMV)," <i>BMC Infectious Diseases</i> , Vol. 5, No. 9., pp. 1-7 (February 2005)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.125USWO	Application Number: 10/518,142
	Applicant: UCKUN ET AL.	
	Filing Date: 12/17/2004	Group Art Unit: UNKNOWN

	Waddick, K. et al., "CD5 antigen-positive B lymphocytes in human B cell ontogeny during fetal development and after autologous bone marrow transplantation," <i>Experimental Hematology</i> , Vol. 21, pp. 791-798 (1993)
	Waddick, K. et al., "In Vitro and In Vivo Antileukemic Activity of B43-Pokeweed Antiviral Protein Against Radiation-Resistant Human B-Cell Precursor Leukemia Cells," <i>Blood</i> , Vol. 86, No. 11, pp. 4228-4233 (December 1, 1995)
	Watanabe, K. et al., "Actions of pokeweed antiviral protein on virus-infected protoplasts," <i>Biosci. Biotechnol. Biochem.</i> , Vol. 61, No. 6, pp. 994-997 (June 1997) (1 page Abstract)
	Waurzyniak, B. et al., "In Vivo Toxicity, Pharmacokinetics, and Antileukemic Activity of TXU (Anti-CD7)-Pokeweed Antiviral Protein Immunotoxin," <i>Clinical Cancer Research</i> , Vol. 3, pp. 881-889 (June 1997)
	Wright, T. et al., "Cervical Intraepithelial Neoplasia in Women Infected with Human Immunodeficiency Virus: Prevalence, Risk Factors, and Validity of Papanicolaou Smears," <i>Obstet. Gynecol.</i> , Vol. 84, No. 4, Part 1, pp. 591-597 (October 1994)
	Zarling, J. et al., "Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4 ⁺ cells by monoclonal antibodies," <i>Nature</i> , Vol. 347, pp. 92-95 (September 6, 1990)
	Zarling, J. et al., "Inhibition of HIV-1 replication in seropositive patients' CD4 ⁺ T-cells by pokeweed antiviral protein - monoclonal antibody conjugates," <i>Int. J. Immunopharmac.</i> , Vol. 13, Suppl. 1, pp. 63-68 (1991)
	Zoubenko, O. et al., "Plant resistance to fungal infection induced by nontoxic pokeweed antiviral protein mutants," <i>Nature Biotechnology</i> , Vol. 15, pp. 992-996 (October 1997)

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	